Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport, Inc. (CYRX) has announced the opening of a new Global Logistics Center in Singapore, aimed at expanding its presence in the Asia Pacific region. This facility enhances capabilities for temperature-controlled supply chain solutions, following the establishment of a similar center in Osaka, Japan, in late 2020. By March 31, 2021, Cryoport supported 543 clinical trials globally, with 28 in the APAC area. Partnerships with companies like Lonza are driving demand for medical therapies, solidifying Cryoport's strategic position in this growing market.
Cryoport, Inc. (NASDAQ: CYRX) announced the acquisition of F-Airgate, a provider of temperature-controlled supply chain solutions based in Brussels, Belgium. This strategic acquisition aims to enhance Cryoport's global network, specifically expanding their operations in the EMEA region. F-Airgate will integrate into Cryoport's CRYOPDP business unit, becoming their 11th European site. The deal is expected to be accretive to earnings in FY 2021 and positions Cryoport to better serve its growing customer base in the life sciences sector.
Cryoport, Inc. (NASDAQ: CYRX) has announced a partnership with LabConnect, Inc. to support Triumvira Immunologics in a Phase I/II clinical trial focused on treating HER2-targeting relapsed solid tumors. The collaboration will leverage Cryoport's Cryoportal® Logistics Management Platform and LabConnect's SampleGISTICS™ platform for efficient logistics and sample tracking. This integrated solution aims to enhance support for clinical program execution, utilizing advanced technologies for near real-time tracking and analytical support in cell and gene therapy trials.
Cryoport, Inc. (NASDAQ: CYRX) reported record financial results for Q1 2021, achieving $53.3 million in revenue, up 445% from $9.8 million in Q1 2020. The Biopharma/Pharma segment led growth, contributing $42.4 million, a 383% increase. The company supported 543 clinical trials, a rise from 465 in the prior year, and announced the acquisition of Critical Transport Solutions Australia to enhance its presence in the APAC region. Operating costs grew to $25.7 million partly due to recent acquisitions, resulting in a net loss of $3.5 million. The company holds $353.2 million in cash as of March 31, 2021.
Cryoport (NASDAQ: CYRX) will announce its first-quarter financial results for 2021 on May 4, 2021, after U.S. markets close. The company will also release a detailed document titled "Cryoport First Quarter 2021 in Review" at 4:05 PM EDT on the same day, providing insights into its financial and operational performance. A conference call for investors is scheduled for 5:00 PM EDT, during which management will address inquiries about the results. The call will be accessible via the company's Investor Relations website.
Cryoport, Inc. (NASDAQ: CYRX) announced the acquisition of Critical Transport Solutions Australia Pty Ltd (CTSA) for approximately USD 5 million. This strategic acquisition enhances Cryoport's healthcare logistics capabilities in Australia, a key market in the APAC region for clinical trials. The deal aims to increase market share and support regenerative medicine therapies. Cryoport's expansion strategy includes recent establishment of a global logistics center in Osaka, Japan. CTSA will operate under Cryoport's CRYOPDP unit, maintaining its current management team.
Cryoport, Inc. (NASDAQ: CYRX) has appointed Linda Baddour to its Board of Directors, effective March 15, 2021. Baddour brings over twenty years of experience in healthcare and life sciences, having previously served as CFO at PRA Health Sciences. CEO Jerrell Shelton emphasized the importance of governance in enhancing growth through their expanded global footprint. Baddour expressed excitement about joining Cryoport as it capitalizes on opportunities in the growing regenerative therapies market.
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for Q4 and FY 2020, reporting significant revenue growth across all sectors. Total revenue soared to $48.4 million in Q4 2020, up 423% from the previous year, and reached $78.7 million for the full year, a 132% increase. Key markets include biopharma/pharma with a 378% Q4 growth, and animal health at 2363%. Despite a net loss of $11.5 million in Q4, the company remains optimistic about 2021, supported by acquisitions and a robust pipeline of clinical trials, now totaling 528. Cryoport's ESG initiatives have also been highlighted as part of their strategic vision.
Cryoport, Inc. (NASDAQ: CYRX) announced its financial results for the fourth quarter and fiscal year ended December 31, 2020 will be reported on March 1, 2021, after U.S. markets close. In conjunction with this, a document titled "Cryoport 2020 Year in Review" will be released, highlighting the company's recent performance and operational updates. A conference call is scheduled for 5:00 PM EST the same day to address investor questions regarding the reported results. The call will also be accessible via webcast.
Summary not available.